SIOX News and Press, Sio Gene Therapies Inc. From 11/01/21

-   Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations -   Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases NEW YORK and DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWI...

Sio used to be called Axovant - an unsuccessful biotech that attempted to bring several therapies to market, including an Alzheimer's treatment. Axovant burned through investors' cash after raising a >$300m IPO in 2015, before abandoning all of its projects and handing control to c...

SIOX presented excellent data in its higher dose GM1 Gangliosidosis gene therapy program. Unfortunately, after hours that same day, its chief research and development officer announced he was moving on to another company. Investors seem to have latched on the latter news rather th...

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, announced today that Gavin Corcoran, M.D., Chief R...

3 Penny Stocks Under $4 For Your Watchlist Right now If you’ve traded penny stocks in 2021, you’re likely used to the high degree of volatility that has become commonplace in the stock market. But, penny stocks also present a great opportunity to capitalize on short or...

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Admini...

Consistent dose-dependent improvements across biomarker measures Normalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts ...

Energous (NASDAQ:WATT) +35% granted FCC approval for unlimited Distance over-the-air wireless charging Edesa Biotech (NASDAQ:EDSA) +29% reports favorable mortality reductions in COVID-19 study InflaRx (NASDAQ:IFRX) +21% after EUR 43.7M vilobelimab development grant En...

ION Geophysical (NYSE:IO) +45% sees Q3 revenues more than doubling Q/Q Valneva SE (NASDAQ:VALN) +36% after topline results from late-stage VLA2001 COVID-19 trial Adamis Pharmaceuticals (NASDAQ:ADMP) +35% after FDA approves opioid overdose treatment ZIMHI MeiraGTx...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...